Tumour Production in Immunosuppressed Rats with Cells
Transformed in vitro by Adenovirus Type 2 (Accepted I8 April I972 )
Serotypes of human adenovirus have been classified by Huebner (1967) into three groups (A, B and C) based on their oncogenicity in hamsters. Rat cells transformed in vitro by viruses from both groups A and B have been reported to produce tumours in new-born rats (Freeman et al. i967b , c) . Some members of Huebner's non-oncogenic group C were subsequently shown to cause morphological transformation of primary rat embryo cells in vitro (Freeman et al. I967a; McAllister et al. I969) . Clones derived from these epithelioid foci are similar in their in vitro characteristics to transformed clones induced by adenovirus in groups A and B. The cells grow to high density in medium with low serum, produce colonies in agar and possess adenovirus specifc tumour antigen (T-antigen). No tumours were produced when cells transformed in vitro by the group C adenoviruses were inoculated into syngeneic neonate rats and it has been suggested that group C adenoviruses induce strong transplantation antigens in the cells they transform (McAllister et al. I969) .
Increased tumorigenicity has been reported for both oncogenic viruses (Allison, Berman & Levey, i967; Sjrgren & Borum, I97I) and chemical carcinogens (Balner & Dersjant, I969; Cerilli & Treat, I969), in animals when anti-lymphocyte serum is used as an immunosuppressive agent. With this in mind, experiments were made to determine whether turnouts would be formed by the inoculation of rat cells transformed by the 'non-oncogenic' human adenovirus type 2 (Ad 2) into rats immunosuppressed by rabbit anti-rat thymocyte serum (ATS). The ATS was prepared by inoculating adult rabbits with I × Io 9 rat thymocytes intravenously, followed at fortnightly intervals with two additional doses of 5 x io 9 rat thymocytes intraperitoneally (IP). Rabbits were bled out by cardiac puncture IO days after the last IP injection. The separated sera from 4 rabbits were pooled and stored at -7o °. Allogeneic skin grafts (Brown Norway rat tail skin) had a 33 day survival time (mean of 8 rats) on the thorax of adult Hooded Lister rats given IP injections of ATS (each o'5 ml.[ rat) on the day before grafting, on the day of grafting, and on the 2 days post grafting. Control rats receiving normal rabbit serum (NRS) according to the same schedule rejected grafts in 9"7 days (mean of 8 rats). The in vitro transformation system used in this study was basically that described by McAllister et al. (i969) .
Two clones from Ad 2 transformed Wistar White rat embryo fibroblasts (Az/REF/I and A2/REF/2) were isolated, characterized by in vitro criteria as transformed cells and inoculated intraperitoneally (3 × Io° cells/rat) into I-day-old Hooded Lister rats. Normal rabbit serum (NRS)and ATS were administered on days Io, I I, I2 and I3 (o-z ml. IP]rat/day). Neonates which had received normal rat embryo fibroblasts (3 × Io6 cells/rat) were also treated with ATS and NRS according to the same schedule.
Tumours were palpable by day 2o in the ATS-treated animals injected with cells from one of the transformed clones (Az]REF/I) and by day 31 in ATS-treated animals injected with cells from the other transformed clone (A2/REF]2). Deaths from invasive tumours occurred as early as day 34 (Table I) . Post mortem examinations revealed many tumours in the peritoneal cavity, infiltration of the liver and secondary tumours in the lungs of all dead rats. Haematoxylin-and eosin-stained tumour sections showed the tumours to be undif- Cells from Hooded Lister rat embryos transformed by adenovirus 2, also produce tumours in immunosuppressed rats from the same closed colony. Cell lines derived from these turnouts by serial passage in vitro produced progressive growing turnouts in a high percentage of the recipients when transplanted into day-old Hooded Lister rats with no immunosuppression. Details of these experiments will be reported at a later date, but these preliminary observations could suggest a selection for cells of lowered antigenicity either in the immunosuppressed primary recipient or during the subsequent period of growth in tissue culture.
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